The purpose of SMA Europe is to provide a framework to stimulate collaboration and accelerate translational research pathways in SMA and promote patient care.

  1. Potential SMA Treatment granted orphan medicinal product designation by the European Medicines Agency (EMA)

    Cytokinetics announced that the European Medicines Agency (EMA) has granted orphan medicinal product designation to reldesemtiv for the potential treatment of SMA. Reldesemtiv is a drug that has been shown, in the laboratory, to increase the force generated by skeletal muscle and which delays the onset and extent of muscle fatigue. This could be beneficial to people living with SMA […]